<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04853095</url>
  </required_header>
  <id_info>
    <org_study_id>FNOl 00098892</org_study_id>
    <nct_id>NCT04853095</nct_id>
  </id_info>
  <brief_title>Effect of Peritoneal Fixation on Lymphocele Formation</brief_title>
  <acronym>PerFix</acronym>
  <official_title>Prospective Randomized Trial Evaluating the Effect of Peritoneal Flap Fixation on Symptomatic and Radiologic Lymphocele Formation Following Robot Assisted Radical Prostatectomy With Extended Pelvic Lymph Node Dissection (PerFix)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Olomouc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Olomouc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PerFix Trial aims to compare the use of peritoneal fixation technique to standard of care&#xD;
      (no fixation) during robot-assisted radical prostatectomy with extended pelvic lymph node&#xD;
      dissection (RARP + eLND) for the prevention of symptomatic and radiologic lymphocele&#xD;
      formation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Extended pelvic lymph node dissection (ePLND) is the most accurate staging tool to determine&#xD;
      lymph node involvement in prostate cancer. As urologist perform this procedure more often&#xD;
      now, thanks to the shift to more advanced and aggressive stages, the role of ePLND is&#xD;
      expanding. The main complication of PLND is development of a collection of lymphatic fluid&#xD;
      called a lymphocele. Lymphoceles can be associated with abdominal pain, lower urinary tract&#xD;
      symptoms, bladder outlet obstruction, penile or scrotal edema, infection/sepsis, lower&#xD;
      extremity swelling and deep vein thrombosis. They necessitate intervention in up to 10% of&#xD;
      patients treated with RARP + ePLND which includes drainage or surgery. Radiologic incidence&#xD;
      can be as high as around 50% of operated patients with unknown clinical relevance. Many&#xD;
      interventions aimed at reducing the rate of lymphocele formation with limited success so far.&#xD;
      Several retrospective studies suggested using peritoneal flap fixation technique which could&#xD;
      direct the lymphatic fluid to the peritoneal cavity out of the pelvis and its ensure its&#xD;
      reabsorption there. We hypothesize that peritoneal fixation can potentially lower the&#xD;
      incidence of symptomatic and radiologic lymphocele formation. By preventing this potentially&#xD;
      very dangerous complication, it could be very beneficial for a large group of patients&#xD;
      suffering from aggressive localized prostate cancer who are scheduled for RARP + ePLND.&#xD;
&#xD;
      Our goal is to is to test this hypothesis in a randomized trial comparing the fixation&#xD;
      technique to standard of care, i.e. no fixation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Symptomatic lymphocele</measure>
    <time_frame>3 months</time_frame>
    <description>The number of participants with symptomatic lymphocele will be determined. Clinical symptoms, time of onset, the size of the lymphocele, location, number of Lymphoceles and intervention needed will be measured</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Radiologic lymphocele on pelvic CT scan</measure>
    <time_frame>3 months</time_frame>
    <description>The number of participants with radiologic lymphocele on Pelvic CT scan will be determined together with the size, location and number of detected lymphoceles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of severe (Clavien grade ≥3) complications</measure>
    <time_frame>3 months</time_frame>
    <description>Incidence of adverse events in the Prefix group compared to control group (no PerFix) will be measured. Surgical complications will be evaluated according to Clavien-Dindo classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lymphocele size</measure>
    <time_frame>1 year</time_frame>
    <description>The change in lymphocele size during follow-up CT scan will be examined</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Occurrence of Any Venous Thromboembolism</measure>
    <time_frame>6 months</time_frame>
    <description>Radiologic investigation will be done in case of by swelling or pain of the lower extremity and the number of any venous thromboembolism will be determined</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative outcomes</measure>
    <time_frame>30 days</time_frame>
    <description>Perioperative outcomes (time of the surgery, blood loss and hospital stay) will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of lymphocele on urinary incontinence</measure>
    <time_frame>1 year</time_frame>
    <description>The rate of continent patients will be defined using pads needed per day. Continent equals to 0-1 pad per day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of lymphocele on potency</measure>
    <time_frame>1 year</time_frame>
    <description>Potency equals to 19 and more points in the International index of erectile function (IIEF5) questionnaire (scale 0-25), the higher the score, the better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of lymphocele on lower urinary tract symptoms (LUTS)</measure>
    <time_frame>1 year</time_frame>
    <description>Change in the International prostate symptom score (IPSS) questionnaire from the baseline will be assessed (scale 0-35, higher score means worse outcome).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Lymphocele After Surgical Procedure</condition>
  <arm_group>
    <arm_group_label>Intervention group (PerFix)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peritoneal fixation technique</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group (no PerFix)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care (i.e. no fixation)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peritoneal fixation (PerFix)</intervention_name>
    <description>PerFix involves suturing the free end of the peritoneal flap left after RARP + ePLND to the pelvic wall near the symphysis of the pubic bones leaving two lateral openings for directing the lymphatic fluid out of the pelvis to the abdominal cavity.</description>
    <arm_group_label>Intervention group (PerFix)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>ePLND without peritoneal flap fixation</description>
    <arm_group_label>Control group (no PerFix)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
          -  Histologically proven high risk prostate cancer or intermediate risk cancer (≥5% risk&#xD;
             of nodal involvement on Briganti 2012 nomogram) according to European Association od&#xD;
             Urology (EAU) risk groups&#xD;
&#xD;
          -  Suitable for minimally-invasive surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous pelvic surgery or irradiation.&#xD;
&#xD;
          -  Any type of clotting disorder.&#xD;
&#xD;
          -  Patients unwilling to undergo CT scan&#xD;
&#xD;
          -  Kidney failure, Hemodialysis&#xD;
&#xD;
          -  American Society of Anesthesiology Classification&gt; 3&#xD;
&#xD;
          -  Existing contraindications for performing a lymph node dissection&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladimir Student, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dpt. of Urology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vladimir Student Jr., MD, PhD</last_name>
    <phone>+420737807881</phone>
    <email>vladastudent@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vladimir Student, prof.</last_name>
    <phone>+420602780396</phone>
    <email>vladimir.student@fnol.cz</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University hospital Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>77900</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir Student Jr., MD, PhD</last_name>
      <phone>+420737807881</phone>
      <email>vladastudent@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Vladimir Student Jr., MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 28, 2021</study_first_submitted>
  <study_first_submitted_qc>April 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2021</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Olomouc</investigator_affiliation>
    <investigator_full_name>Vladimir Student, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Vladimir Student Jr., MD, PhD, FEBU</investigator_title>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>Robot-assisted radical prostatectomy</keyword>
  <keyword>Extended pelvic lymph node dissection</keyword>
  <keyword>Lymphocele</keyword>
  <keyword>Peritoneal fixation</keyword>
  <keyword>Lymphatic disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Lymphocele</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

